Sarah Missel
Vice President - Bispecifics Portfolio Development Immatics N.V.
Sarah Missel is Vice President and Development Lead for Immatics’ TCE (TCER®) pipeline and portfolio. This includes the translation of preclinical projects into early phase clinical trials as well as leadership for clinical stage TCER® programs. Sarah is a Pharmacist and holds a PhD in Virology.
Seminars
Wednesday 10th December 2025
Addressing Intracellular Targets in Oncology: The PRAME TCER™ Journey
9:30 am
• Engaging PRAME peptide–HLA complexes
• Optimising TCE format and design for intracellular pHLA targeting to maximise potency, specificity, manufacturability and half-life
• Efficiently translating preclinical findings into clinical results
